ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $22.32: Concentration risk — Product: NUPLAZID and DAYBUE; Cyclical risk: PE expanding 2.4x (earnings normalizing).
ACADIA Pharmaceuticals is a biopharmaceutical company commercializing two products: NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome, with combined net product sales of $1,071.5 million in 2025. Both are the first and only... Read more
Sell if holding. Multiple concerning factors at $22.32: Concentration risk — Product: NUPLAZID and DAYBUE; Cyclical risk: PE expanding 2.4x (earnings normalizing). Chart setup: Death cross but MACD improving, RSI 56. Score 6.2/10, moderate confidence.
Passes 5/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductNUPLAZID and DAYBUE10-K Item 1A: 'Our prospects are highly dependent on the successful commercialization of our products ... NUPLAZID and DAYBUE'
Material Events(8-K, last 90d)
- 2026-03-05Item 5.02LOWJonathan M. Poole appointed to Board as Class II director and Audit Committee member effective March 3, 2026. Routine board appointment to fill vacancy.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $22.32: Concentration risk — Product: NUPLAZID and DAYBUE; Cyclical risk: PE expanding 2.4x (earnings normalizing). Chart setup: Death cross but MACD improving, RSI 56. Prior stop was $21.03. Score 6.2/10, moderate confidence.
Take-profit target: $28.53 (+28.0% upside). Prior stop was $21.03. Stop-loss: $21.03.
Concentration risk — Product: NUPLAZID and DAYBUE; Cyclical risk: PE expanding 2.4x (earnings normalizing); Leverage penalty (D/E 4.3): -1.5.
ACADIA Pharmaceuticals Inc. trades at a P/E of 9.7 (forward 23.3). TrendMatrix value score: 7.2/10. Verdict: Sell.
27 analysts cover ACAD with a consensus score of 4.0/5. Average price target: $32.
What does ACADIA Pharmaceuticals Inc. do?ACADIA Pharmaceuticals is a biopharmaceutical company commercializing two products: NUPLAZID (pimavanserin) for...
ACADIA Pharmaceuticals is a biopharmaceutical company commercializing two products: NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome, with combined net product sales of $1,071.5 million in 2025. Both are the first and only FDA-approved drugs for their respective indications. The pipeline includes remlifanserin (ACP-204) for Alzheimer's disease psychosis in Phase 2 trials.